Skip to main content

The Landmark Series: Pancreatic Neuroendocrine Tumors


Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of neoplasms arising from pancreatic islet cells that remain relatively rare but are increasing in incidence worldwide. While significant advances have been made in recent years with regard to systemic therapies for patients with advanced disease, surgical resection remains the standard of care for most patients with localized tumors. Although formal pancreatectomy with regional lymphadenectomy is the standard approach for most PNETs, pancreas-preserving approaches without formal lymphadenectomy are acceptable for smaller tumors at low risk for lymph node metastases. Furthermore, observation of small, asymptomatic, low-grade PNETs is a safe, initial strategy and is generally recommended for tumors < 1 cm in size. In this Landmark Series review, we highlight the critical studies that have defined the surgical management of PNETs.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Cloyd J, Poultsides G. Neoplasms of the Endocrine Pancreas. In: Dimick J, Upchurch G, Alam H, Pawlik TM, Hawn M, Sosa JA (eds). Mulholland and greenfield’s surgery: scientific principles & practice. 7th ed. Wolters Kluwer Health, Philadelphia.

  2. 2.

    Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18.

    Article  PubMed  Google Scholar 

  3. 3.

    Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: advances in diagnosis and management. World J Gastroenterol. 2015;21(32):9512–25.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Zhang IY, Zhao J, Fernandez-del Castillo C, et al. Operative versus nonoperative management of nonfunctioning pancreatic neuroendocrine tumors. J Gastrointest Surg. 2016;20(2):277–83.

    Article  PubMed  Google Scholar 

  6. 6.

    Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115(4):741–51.

    Article  PubMed  Google Scholar 

  7. 7.

    Assi HA, Mukherjee S, Kunz PL, et al. Surgery versus surveillance for well-differentiated, nonfunctional pancreatic neuroendocrine tumors: an 11-year analysis of the national cancer database. Oncol. 2020;25(2):e276–83.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Haugvik S-P, Labori KJ, Waage A, Line P-D, Mathisen Ø, Gladhaug IP. Pancreatic surgery with vascular reconstruction in patients with locally advanced pancreatic neuroendocrine tumors. J Gastrointest Surg. 2013;17(7):1224–32.

    Article  PubMed  Google Scholar 

  9. 9.

    Cloyd JM, Wiseman JT, Pawlik TM. Surgical management of pancreatic neuroendocrine liver metastases. J Gastrointest Oncol. 2020;11(3):590–600.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Almond LM, Hodson J, Ford SJ, et al. Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2017;43(10):1808–15.

    CAS  Article  Google Scholar 

  11. 11.

    Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Howe JR, Merchant NB, Conrad C, et al. The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1–33.

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Grimelius L, Hultquist GT, Stenkvist B. Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol Anat Histol. 1975;365(4):275–88.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas: analysis of autopsy cases. Dig Dis Sci. 1991;36(7):933–42.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Sadot E, Reidy-Lagunes DL, Tang LH, et al. Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: a matched case-control study. Ann Surg Oncol. 2016;23(4):1361–70.

    Article  PubMed  Google Scholar 

  16. 16.

    Gaujoux S, Partelli S, Maire F, et al. Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2013;98(12):4784–9.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Lee LC, Grant CS, Salomao DR, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012;152(6):965–74.

    Article  PubMed  Google Scholar 

  18. 18.

    Yohanathan L, Dossa F, St Germain AT, et al. Management and surveillance of non-functional pancreatic neuroendocrine tumours: retrospective review. Pancreatol. 2019;19(2):360–6.

    Article  Google Scholar 

  19. 19.

    Partelli S, Cirocchi R, Crippa S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg. 2017;104(1):34–41.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Sinclair TJ, Poultsides GA. Islet tumors: Resect or follow? Adv Surg. 2020;54:69–88.

    Article  PubMed  Google Scholar 

  21. 21.

    Poultsides GA, Huang LC, Chen Y, et al. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Ann Surg Oncol. 2012;19(7):2295–303.

    Article  PubMed  Google Scholar 

  22. 22.

    Dong D-H, Zhang X-F, Poultsides G, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm after curative resection: a multi-institutional study of 392 cases. J Surg Oncol. 2019;120(7):1071–9.

    Article  PubMed  Google Scholar 

  23. 23.

    Cherenfant J, Stocker SJ, Gage MK, et al. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2013;154(4):785–91; discussion 791–3.

  24. 24.

    Ricci C, Casadei R, Taffurelli G, et al. Sporadic small (≤ 20 mm) nonfunctioning pancreatic neuroendocrine neoplasm: is the risk of malignancy negligible when adopting a more conservative strategy? A systematic review and meta-analysis. Ann Surg Oncol. 2017;24(9):2603–10.

    Article  PubMed  Google Scholar 

  25. 25.

    Sallinen V, Le Large TYS, Galeev S, et al. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors: a systematic review and meta-analysis. HPB. 2017;19(4):310–20.

    Article  PubMed  Google Scholar 

  26. 26.

    Finkelstein P, Sharma R, Picado O, et al. Pancreatic neuroendocrine tumors (panNETs): analysis of overall survival of nonsurgical management versus surgical resection. J Gastrointest Surg. 2017;21(5):855–66.

    Article  PubMed  Google Scholar 

  27. 27.

    Kurita Y, Hara K, Kuwahara T, et al. Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis. J Gastroenterol. 2020;55(5):543–52.

    Article  PubMed  Google Scholar 

  28. 28.

    Barenboim A, Lahat G, Nachmany I, et al. Resection Versus Observation of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors. J Gastrointest Surg. 2020;24(6):1366–74.

    Article  PubMed  Google Scholar 

  29. 29.

    Rosenberg AM, Friedmann P, Del Rivero J, Libutti SK, Laird AM. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors. Surgery. 2016;159(1):302–9.

    Article  PubMed  Google Scholar 

  30. 30.

    Regenet N, Carrere N, Boulanger G, et al. Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: a French multicenter study. Surgery. 2016;159(3):901–7.

    Article  PubMed  Google Scholar 

  31. 31.

    Singh S, Dey C, Kennecke H, et al. Consensus recommendations for the diagnosis and management of pancreatic neuroendocrine tumors: guidelines from a canadian national expert group. Ann Surg Oncol. 2015;22(8):2685–99.

    Article  PubMed  Google Scholar 

  32. 32.

    Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95(2):120–34.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Yang G, Ji M, Chen J, et al. Surgery management for sporadic small (≤ 2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET). Int J Oncol. 2017;50(2):567–74.

    Article  PubMed  Google Scholar 

  34. 34.

    Mansour JC, Chavin K, Morris-Stiff G, et al. Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. HPB. 2019;21(5):515–23.

    Article  PubMed  Google Scholar 

  35. 35.

    National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors. Version 2.2020. Available at: Accessed 5 Aug 2020.

  36. 36.

    Tanaka M, Heckler M, Mihaljevic AL, et al. Systematic review and metaanalysis of lymph node metastases of resected pancreatic neuroendocrine tumors. Ann Surg Oncol. Published online July 27, 2020.

  37. 37.

    Krampitz GW, Norton JA, Poultsides GA, Visser BC, Sun L, Jensen RT. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg Chic Ill 1960. 2012;147(9):820–7.

  38. 38.

    Gratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA. Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. Ann Surg Oncol. 2014;21(11):3515–21.

    Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Mao R, Zhao H, Li K, et al. Outcomes of lymph node dissection for non-metastatic pancreatic neuroendocrine tumors: a propensity score-weighted analysis of the national cancer database. Ann Surg Oncol. 2019;26(9):2722–9.

    Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Conrad C, Kutlu OC, Dasari A, et al. Prognostic value of lymph node status and extent of lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas. J Gastrointest Surg. 2016;20(12):1966–74.

    Article  PubMed  Google Scholar 

  41. 41.

    Sahara K, Tsilimigras DI, Mehta R, et al. Trends in the number of lymph nodes evaluated among patients with pancreatic neuroendocrine tumors in the United States: a multi-institutional and national database analysis. Ann Surg Oncol. 2020;27(4):1203–12.

    Article  PubMed  Google Scholar 

  42. 42.

    Zhang X-F, Xue F, Dong D-H, et al. New nodal staging for primary pancreatic neuroendocrine tumors: a multi-institutional and national data analysis. Ann Surg. Published online July 26, 2019.

  43. 43.

    Wu L, Sahara K, Tsilimigras DI, et al. Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: a multi-institutional analysis. J Surg Oncol. 2019;120(7):1080–6.

    Article  PubMed  Google Scholar 

  44. 44.

    Partelli S, Gaujoux S, Boninsegna L, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). JAMA Surg. 2013;148(10):932–9.

    Article  PubMed  Google Scholar 

  45. 45.

    Postlewait LM, Ethun CG, Baptiste GG, et al. Pancreatic neuroendocrine tumors: preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol. 2016;114(4):440–5.

    Article  PubMed  Google Scholar 

  46. 46.

    Mizumoto T, Toyama H, Terai S, et al. Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics. Pancreatol. 2017;17(6):956–61.

    Article  Google Scholar 

  47. 47.

    Worhunsky DJ, Krampitz GW, Poullos PD, et al. Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB. 2014;16(4):304–11.

    Article  PubMed  Google Scholar 

  48. 48.

    Cloyd JM, Kopecky KE, Norton JA, et al. Neuroendocrine tumors of the pancreas: degree of cystic component predicts prognosis. Surgery. 2016;160(3):708–13.

    Article  PubMed  Google Scholar 

  49. 49.

    Cloyd JM, Pawlik TM. Minimally invasive hepatopancreatobiliary surgery: Where do we go from here? Surg Oncol. 2018;27(1):A2–4.

    Article  PubMed  Google Scholar 

  50. 50.

    Drymousis P, Raptis DA, Spalding D, et al. Laparoscopic versus open pancreas resection for pancreatic neuroendocrine tumours: a systematic review and meta-analysis. HPB. 2014;16(5):397–406.

    Article  PubMed  Google Scholar 

  51. 51.

    Tamburrino D, Partelli S, Renzi C, et al. Systematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNENs). Expert Rev Gastroenterol Hepatol. 2017;11(1):65–73.

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    de Rooij T, van Hilst J, van Santvoort H, et al. Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann Surg. 2019;269(1):2–9.

    Article  PubMed  Google Scholar 

  53. 53.

    Vollmer CM, Asbun HJ, Barkun J, et al. Proceedings of the first international state-of-the-art conference on minimally-invasive pancreatic resection (MIPR). HPB. 2017;19(3):171–7.

    Article  PubMed  Google Scholar 

  54. 54.

    Asbun HJ, Moekotte AL, Vissers FL, et al. The miami international evidence-based guidelines on minimally invasive pancreas resection. Ann Surg. 2020;271(1):1–14.

    Article  PubMed  Google Scholar 

  55. 55.

    Daouadi M, Zureikat AH, Zenati MS, et al. Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg. 2013;257(1):128–32.

    Article  PubMed  Google Scholar 

  56. 56.

    Guerrini GP, Lauretta A, Belluco C, et al. Robotic versus laparoscopic distal pancreatectomy: an up-to-date meta-analysis. BMC Surg. 2017;17(1):105.

    Article  PubMed  PubMed Central  Google Scholar 

  57. 57.

    van Hilst J, de Rooij T, Bosscha K, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol. 2019;4(3):199–207.

    Article  PubMed  Google Scholar 

  58. 58.

    Strobel O, Büchler MW. Laparoscopic pancreatoduodenectomy: safety concerns and no benefits. Lancet Gastroenterol Hepatol. 2019;4(3):186–7.

    Article  PubMed  Google Scholar 

  59. 59.

    Ricci C, Casadei R, Taffurelli G, Pacilio CA, Ricciardiello M, Minni F. Minimally invasive pancreaticoduodenectomy: What is the best “choice”? A systematic review and network meta-analysis of non-randomized comparative studies. World J Surg. 2018;42(3):788–805.

    Article  PubMed  Google Scholar 

  60. 60.

    Watkins AA, Kent TS, Gooding WE, et al. Multicenter outcomes of robotic reconstruction during the early learning curve for minimally-invasive pancreaticoduodenectomy. HPB. 2018;20(2):155–65.

    Article  PubMed  Google Scholar 

  61. 61.

    Boone BA, Zenati M, Hogg ME, et al. Assessment of quality outcomes for robotic pancreaticoduodenectomy: identification of the learning curve. JAMA Surg. 2015;150(5):416–22.

    Article  PubMed  Google Scholar 

  62. 62.

    Zureikat AH, Postlewait LM, Liu Y, et al. A Multi-institutional comparison of perioperative outcomes of robotic and open pancreaticoduodenectomy. Ann Surg. 2016;264(4):640–9.

    Article  PubMed  Google Scholar 

  63. 63.

    Hüttner FJ, Koessler-Ebs J, Hackert T, Ulrich A, Büchler MW, Diener MK. Meta-analysis of surgical outcome after enucleation versus standard resection for pancreatic neoplasms. Br J Surg. 2015;102(9):1026–36.

    Article  PubMed  Google Scholar 

  64. 64.

    Dragomir MP, Sabo AA, Petrescu GED, Li Y, Dumitrascu T. Central pancreatectomy: a comprehensive, up-to-date meta-analysis. Langenbecks Arch Surg. 2019;404(8):945–58.

    Article  PubMed  Google Scholar 

  65. 65.

    Dalla Valle R, Cremaschi E, Lamecchi L, Guerini F, Rosso E, Iaria M. Open and minimally invasive pancreatic neoplasms enucleation: a systematic review. Surg Endosc. 2019;33(10):3192–9.

    Article  PubMed  Google Scholar 

  66. 66.

    Wakabayashi T, Felli E, Cherkaoui Z, Mutter D, Marescaux J, Pessaux P. Robotic central pancreatectomy for well-differentiated neuroendocrine tumor: parenchymal-sparing procedure. Ann Surg Oncol. 2019;26(7):2121.

    Article  PubMed  Google Scholar 

  67. 67.

    Sahara K, Tsilimigras DI, Moro A, et al. Long-term outcomes after spleen-preserving distal pancreatectomy for pancreatic neuroendocrine tumors: results from the us neuroendocrine study group. Neuroendocrinology. Published online February 11, 2020.

  68. 68.

    Pendola F, Gadde R, Ripat C, et al. Distal pancreatectomy for benign and low grade malignant tumors: Short-term postoperative outcomes of spleen preservation—a systematic review and update meta-analysis. J Surg Oncol. 2017;115(2):137–43.

    Article  PubMed  Google Scholar 

  69. 69.

    Mehrabi A, Fischer L, Hafezi M, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas. 2014;43(5):675–86.

    Article  PubMed  Google Scholar 

  70. 70.

    Bartsch DK, Waldmann J, Fendrich V, et al. Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg. 2012;99(9):1234–40.

    CAS  Article  PubMed  Google Scholar 

  71. 71.

    Cloyd J, Lee J. Pancreatic neuroendocrine tumors and multiple endocrine neoplasia. In: The MD Anderson Surgical Oncology Handbook. 6th Edition. Feig B and Ching D. Wolters Kluwer; 2019.

  72. 72.

    Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA. Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025-6. Arch Surg Chic Ill 1960. 2001;136(9):1020–5.

  73. 73.

    Thom AK, Norton JA, Doppman JL, Miller DL, Chang R, Jensen RT. Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery. 1992;112(6):1002–8; discussion 1008–9.

  74. 74.

    Sadowski SM, Pieterman CRC, Perrier ND, Triponez F, Valk GD. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature. Endocr Relat Cancer. 2020;27(6):R145–61.

    CAS  Article  PubMed  Google Scholar 

  75. 75.

    Triponez F, Sadowski SM, Pattou F, et al. Long-term follow-up of MEN1 patients who do not have initial surgery for small ≤ 2 cm nonfunctioning pancreatic neuroendocrine tumors, an AFCE and GTE study: association Francophone de Chirurgie Endocrinienne & Groupe d’Etude des Tumeurs Endocrines. Ann Surg. 2018;268(1):158–64.

    Article  PubMed  Google Scholar 

  76. 76.

    Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240(5):757–73.

    Article  PubMed  PubMed Central  Google Scholar 

  77. 77.

    Norton JA, Foster DS, Ito T, Jensen RT. Gastrinomas: medical or surgical treatment. Endocrinol Metab Clin North Am. 2018;47(3):577–601.

    Article  PubMed  PubMed Central  Google Scholar 

  78. 78.

    Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234(4):495–505; discussion 505–6.

  79. 79.

    Cloyd JM, Konda B, Shah MH, Pawlik TM. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Rev Clin Pharmacol. 2019;12(2):101–8.

    CAS  Article  PubMed  Google Scholar 

  80. 80.

    Squires MH, Worth PJ, Konda B, et al. Neoadjuvant capecitabine/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors. Pancreas. 2020;49(3):355–60.

    CAS  Article  PubMed  Google Scholar 

  81. 81.

    Prakash L, Bhosale P, Cloyd J, et al. Role of fluorouracil, doxorubicin, and streptozocin therapy in the preoperative treatment of localized pancreatic neuroendocrine tumors. J Gastrointest Surg. 2017;21(1):155–63.

    Article  PubMed  Google Scholar 

  82. 82.

    Cloyd JM, Omichi K, Mizuno T, et al. Preoperative fluorouracil, doxorubicin, and streptozocin for the treatment of pancreatic neuroendocrine liver metastases. Ann Surg Oncol. 2018;25(6):1709–15.

    Article  PubMed  PubMed Central  Google Scholar 

  83. 83.

    Partelli S, Bertani E, Bartolomei M, et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2018;163(4):761–7.

    Article  PubMed  Google Scholar 

  84. 84.

    Genç CG, Jilesen AP, Partelli S, et al. A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg. 2018;267(6):1148–54.

    Article  PubMed  Google Scholar 

  85. 85.

    Barrett JR, Rendell V, Pokrzywa C, et al. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. J Surg Oncol. 2020;121(7):1067–73.

    CAS  Article  PubMed  Google Scholar 

  86. 86.

    Xie H, Liu J, Yadav S, et al. The role of perioperative systemic therapy in localized pancreatic neuroendocrine neoplasms. Neuroendocrinology. Published online May 24, 2019.

  87. 87.

    Arvold ND, Willett CG, Fernandez-del Castillo C, et al. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(3):e337–43.

    Article  PubMed  Google Scholar 

  88. 88.

    Zagar TM, White RR, Willett CG, et al. Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(4):1126–31.

    Article  PubMed  Google Scholar 

  89. 89.

    Maire F, Hammel P, Kianmanesh R, et al. Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery. 2009;145(1):69–75.

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to George A. Poultsides MD, MS.

Ethics declarations


Jordan M. Cloyd and George A. Poultsides declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cloyd, J.M., Poultsides, G.A. The Landmark Series: Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 28, 1039–1049 (2021).

Download citation